MedTrace Logo

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

NCT06250972 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-08-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of chemotherapy plus radiotherapy to patients with CA19-9-elevated Advanced Pancreatic Cancer who are not refractory to chemotherapy.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

Gemcitabine, Nab-paclitaxel, Irinotecan

continuing chemotherapy using the previous regimen until disease progression

RADIATION

Intensity-Modulated Radiation Therapy (IMRT)

Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Guopei Luo, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2027-05-01
Completion
2028-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06250972 on ClinicalTrials.gov